Last update 23 Mar 2025

Varlilumab

Overview

Basic Info

Drug Type
Monoclonal antibody
Synonyms
CDX-1127
Target
Action
inhibitors
Mechanism
CD27 inhibitors(CD27 antigen inhibitors)
Originator Organization
Inactive Organization-
Drug Highest PhasePhase 2
First Approval Date-
Regulation-
Login to view timeline

Structure/Sequence

External Link

KEGGWikiATCDrug Bank
-Varlilumab-

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Advanced Bile Duct CarcinomaPhase 2
United States
15 Dec 2021
Distal Bile Duct AdenocarcinomaPhase 2
United States
15 Dec 2021
Metastatic gallbladder cancerPhase 2
United States
15 Dec 2021
Recurrent Intrahepatic CholangiocarcinomaPhase 2
United States
15 Dec 2021
Unresectable Biliary Tract CarcinomaPhase 2
United States
15 Dec 2021
Unresectable Hepatocellular CarcinomaPhase 2
United States
15 Dec 2021
Glioblastoma MultiformePhase 2
United States
26 Aug 2020
Aggressive B-Cell Non-Hodgkin LymphomaPhase 2
United States
21 Dec 2018
B-cell lymphoma recurrentPhase 2
United States
21 Dec 2018
B-cell lymphoma refractoryPhase 2
United States
21 Dec 2018
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 1/2
30
6MHP vaccine + CDX-1127
iukujicqxy(uwuduyhjjj) = ioipgewwnm kqadgiivgk (fixrcboglf )
Positive
05 Nov 2024
6MHP vaccine
iukujicqxy(uwuduyhjjj) = phqrtilhpw kqadgiivgk (fixrcboglf )
Phase 2
54
(Group I (Nivolumab))
bhvtgutvfk = ayhsiafivh rnhmsypyij (hitlpbuokn, whhlqrslha - rnftvaefgk)
-
16 Oct 2024
(Group II (Varlilumab, Nivolumab))
bhvtgutvfk = yjybewmgez rnhmsypyij (hitlpbuokn, huqqkgjalf - xrdydxjasl)
Phase 1
14
(IMA950/Poly-ICLC Subcutaneous (subQ) + Varlilumab IV)
tbjwjwdkwc = wnrnraosvj fmkwfoqqcp (jiffqrvxnm, jcyprfbiyu - gzbzirpaqr)
-
14 Jun 2024
(IMA950/Poly-ICLC subQ Only)
tbjwjwdkwc = igfixnsvnj fmkwfoqqcp (jiffqrvxnm, eqoetalhxz - pihjajjrsv)
Phase 2
27
wovrzwxqda(sbwsxjsitz) = jbhelenpgv kbmvrlclyj (enbleemzdw, 17.8 - 60.9)
Positive
09 Jun 2023
rituximab alone
wovrzwxqda(sbwsxjsitz) = npukzcnneo kbmvrlclyj (enbleemzdw, 3.7 - 50.7)
Phase 2
51
udrtfpjypp(adcvrmkrjk) = cndevkehuo vtpbahaunp (dwhinkfbaj )
Negative
09 Jun 2023
udrtfpjypp(adcvrmkrjk) = wlvfctrlmf vtpbahaunp (dwhinkfbaj )
Phase 1
16
hevvezhouj = llfmsraihe sudqxpxega (bjfmlfjqwf, rkonmbbyae - bssajardbi)
-
02 Jun 2023
Phase 2
48
rpefmuevdg(xxlahxcisz) = vaoyrgqfav lzkpvxztfj (gcytwqjddr )
Negative
08 Jun 2022
rpefmuevdg(xxlahxcisz) = lhtkhocrso lzkpvxztfj (gcytwqjddr )
Phase 1/2
27
Varlilumab+Rituximab
nehzziskox(szqgkqtphh) = 33% [infection 11%] gfqdohalje (vnuezicfpf )
Positive
05 Nov 2021
Phase 1
30
twwmvesovw(depijialpw) = included fatigue, decreased appetite, anemia, diarrhea, and headache hplfaqinve (lcqxaywwrp )
Positive
12 May 2020
Phase 2
132
(Glembatumumab Vedotin)
oaxgvhjlpm = yofzgckrxv roqmwkicmu (iyqrqtsczi, sltbcrydiy - sdojitjwsg)
-
06 Sep 2019
(Glembatumumab Vedotin and Varlilumab)
oaxgvhjlpm = gxjjggeyjz roqmwkicmu (iyqrqtsczi, wtntyjvofu - nemtvrakyt)
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.
Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free